Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sangamo and MaxCyte ink licensing deal
The two companies have initiated an R&D plan to evaluate and further develop the GMP-compliant MaxCyte system to load zinc finger DNA-binding protein (ZFP)-based therapeutics into cells. Sangamo
The two companies have initiated an R&D plan to evaluate and further develop the GMP-compliant MaxCyte system to load zinc finger DNA-binding protein (ZFP)-based therapeutics into cells. Sangamo
NicOx has given Pfizer exclusive rights, across the entire field of ophthalmology, to use its proprietary nitric oxide-donating technology. Pfizer will make payments of $27.3 million in the
The companies are specifically seeking approval for use of their drug as an add-on therapy to a common class of oral diabetes medications called thiazolidinediones, or TZDs, for
The non-approvable letter stated that additional information would be required to address remaining questions. BDSI says that it has requested a meeting with the FDA regarding their notification
Abbott claimed, among other things, that Takeda earned excessive profits from its supply of lansoprazole to TAP Pharmaceutical Products, a company jointly owned by Takeda and Abbott. Abbott
It is hoped that the nanotechnology devices being developed will be able to enter living cancer cells and then report back on what is going on inside them.
Pfizer has also acquired the rights to the Exubera insulin production facilities located in Frankfurt, Germany, which were previously jointly owned by the companies. Exubera, the first inhalable
Ceftobiprole showed a high cure rate and was safe and well tolerated. This first-in-class anti-MRSA broad-spectrum cephalosporin is being developed in partnership with Cilag AG International, a Johnson
The agency’s decision comes in response to Medivation’s investigational new drug application (IND), which was filed on January 31, 2006. “Based on the information we have from FDA
If approved, Cimzia (certolizumab pegol, CDP870) would be the first-ever biologic utilizing subcutaneous injection for the treatment of Crohn’s disease. It is the first and only PEGylated Fab’